Mitch McConnell. Photo: Tom Williams/CQ-Roll Call via Getty Images

The Senate voted via unanimous consent on Monday to hold another pro forma session Tuesday afternoon, giving the White House and Congress another day to hammer out the details of the interim coronavirus spending package.

Why it matters: A vote on the bill is expected tomorrow, but the Trump administration and House and Senate leadership were hopeful they would reach a deal this morning to replenish the small business Paycheck Protection Program (PPP) and deliver billions of emergency funding for hospitals and testing.

  • Negotiations over the specifics in the bill, including how the new money for hospitals and expanded federal testing will be administered and how it will be split up among the public and private sectors, are ongoing.

Details: The main details of the bill, as Axios reported on Sunday, remain the same.

  • The bill is still expected to include at least $300 billion more for the PPP, $75 billion for hospitals, $50 billion for the Economic Injury Disaster Loan program, and $25 billion to expand coronavirus testing.
  • Tomorrow's pro forma session is scheduled for 4pm.

What we're hearing: Senior House and Senate aides tell Axios they are confident a deal will be reached in the next 24 hours — and that the bill will be signed into law by the end of the week.

Go deeper

South Carolina caterer: Loans kept many businesses afloat during COVID pandemic

Axios' Sara Fischer (L) and Sameka Jenkins, owner Carolima’s Lowcountry Cuisine. Photo: Axios screenshot.

Many small businesses would have gone under without financial aid during widespread closures caused by the coronavirus pandemic, Carolima’s Lowcountry Cuisine owner Sameka Jenkins said at an Axios virtual event Tuesday.

Zoom in: Jenkins said her South Carolina-based company received an Economic Injury Disaster Loan from the Small Business Administration to ease the financial effects of the crisis.

Jul 28, 2020 - Health

Pfizer beats Wall Street's expectations amid pandemic

Pfizer tallied a 29% profit margin in Q2. Photo: Erik McGregor/LightRocket via Getty Images

Drug sales at Pfizer dipped 11% in the second quarter, totaling $11.8 billion, but the pharmaceutical giant still reported more than $3.4 billion in net profits, or $0.78 in adjusted earnings per share — 15% above what Wall Street expected.

The big picture: The coronavirus pandemic only had a marginal effect on Pfizer, as the declining revenue was mostly due to lower sales from drugs that lost their patent protection. The focus is now on Pfizer's and BioNTech's coronavirus vaccine candidate, which started its late-stage clinical trial this week.

Updated Oct 7, 2020 - Health

World coronavirus updates

Expand chart
Data: The Center for Systems Science and Engineering at Johns Hopkins; Map: Axios Visuals

New Zealand now has active no coronavirus cases in the community after the final six people linked to the Auckland cluster recovered, the country's Health Ministry confirmed in an email Wednesday.

The big picture: The country's second outbreak won't officially be declared closed until there have been "no new cases for two incubation periods," the ministry said. Auckland will join the rest of NZ in enjoying no domestic restrictions from late Wednesday, Prime Minister Jacinda Ardern said, declaring that NZ had "beat the virus again."